Oral treatment shows promise for persistent eosinophilic asthma An early trial of the experimental oral asthma therapy fevipiprant has shown it is effective in reducing airway inflammation among patients with persistent eosinophilic asthma.…
How to help patients optimise their inhaler technique Examining the impact of sub-optimal inhaler technique and how healthcare professionals can support patients in optimising their technique.…
European Medicines Agency announces safety review of prolonged-release paracetamol A safety review of modified and prolonged-release paracetamol has been launched following reported cases of acute overdose, the European Medicine’s Agency has announced.…
FDA approves first buprenorphine implant for opioid dependence The US Food and Drug Administration (FDA) has approved the first buprenorphine implant for the maintenance treatment of opioid dependence in adults, a treatment that is being hailed as “a game changer”.…
First self-administered monthly injection for multiple sclerosis approved in the US Zinbryta (daclizumab), the first once-monthly self-administered injection for multiple sclerosis (MS), has been approved by the US Food and Drug Administration.…
Once-a-day suncreams may not offer long-lasting protection The SPF level of once-a-day suncreams fell by 74% after six to eight hours, according to the results of a test carried out by Which?…
Combining long-acting bronchodilators shows efficacy in COPD Combining the long-acting beta-agonist (LABA) indacaterol plus long-acting muscarinic antagonist (LAMA) glycopyrronium is more effective than salmeterol plus fluticasone in preventing exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbation durin…
Hydromorphone could prevent opioid addicts from using street heroin Analgesic dihydromorphone is as effective as diacetylmorphine (medical grade heroin) in preventing opioid addicts from using heroin bought on the street, reveals a new study.…
FDA approves injectable psoriasis drug The US Food and Drug Administration has approved an injectable treatment, ixekizumab (Taltz; Eli Lilly), for adults with moderate to severe plaque psoriasis. …
FDA approves coagulation factor-albumin fusion protein to treat haemophilia B Idelvion, a coagulation factor-albumin fusion protein product for use in children and adults with haemophilia B, has been approved by the US Food and Drug Administration.…
